GT Biopharma, Inc. issued the following announcement on Jan. 20.
GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager, TriKE® protein biologic technology platform, announced today that Dr. Greg Berk, President of R&D, Chief Medical Officer and Interim CEO will be participating in a Fireside Chat at the upcoming B. Riley Securities' Virtual Oncology Conference.
Details for the presentations are as follows:
B. Riley Oncology Conference
Date: January 27, 2022
Time: 9:30 A.M. EST
Webcast Participation: https://www.webcaster4.com/Webcast/Page/2828/44091
For additional information regarding the conference please contact B. Riley at events@brileyfin.com.
Original source can be found here.
Source: GT Biopharma, Inc.
Alerts Sign-up